370 related articles for article (PubMed ID: 20857056)
1. [Recent progress and novel perspectives on obesity pharmacotherapy].
Faria AM; Mancini MC; Melo ME; Cercato C; Halpern A
Arq Bras Endocrinol Metabol; 2010 Aug; 54(6):516-29. PubMed ID: 20857056
[TBL] [Abstract][Full Text] [Related]
2. New and emerging drug molecules against obesity.
George M; Rajaram M; Shanmugam E
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):65-76. PubMed ID: 24064009
[TBL] [Abstract][Full Text] [Related]
3. Overview of new antiobesity drugs.
Hainer V
Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
[TBL] [Abstract][Full Text] [Related]
4. Current Drug Targets in Obesity Pharmacotherapy - A Review.
Bhat SP; Sharma A
Curr Drug Targets; 2017; 18(8):983-993. PubMed ID: 28245771
[TBL] [Abstract][Full Text] [Related]
5. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
Srivastava G; Apovian C
Curr Obes Rep; 2018 Jun; 7(2):147-161. PubMed ID: 29504049
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and safety of the new anti-obesity medications.
Hainer V; Aldhoon-Hainerová I
Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
Gadde KM; Pritham Raj Y
Curr Diab Rep; 2017 May; 17(5):34. PubMed ID: 28378293
[TBL] [Abstract][Full Text] [Related]
8. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy of obesity: Available medications and drugs under investigation.
Pilitsi E; Farr OM; Polyzos SA; Perakakis N; Nolen-Doerr E; Papathanasiou AE; Mantzoros CS
Metabolism; 2019 Mar; 92():170-192. PubMed ID: 30391259
[TBL] [Abstract][Full Text] [Related]
10. Drug treatment of obesity: current status and future prospects.
Kakkar AK; Dahiya N
Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
[TBL] [Abstract][Full Text] [Related]
11. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Verpeut JL; Bello NT
Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
[TBL] [Abstract][Full Text] [Related]
12. [Drug treatment of obesity--current situation and perspectives].
Hainer V
Cas Lek Cesk; 2010; 149(11):513-9. PubMed ID: 21391349
[TBL] [Abstract][Full Text] [Related]
13. Obesity Pharmacotherapy.
Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
[TBL] [Abstract][Full Text] [Related]
14. Centrally Acting Agents for Obesity: Past, Present, and Future.
Coulter AA; Rebello CJ; Greenway FL
Drugs; 2018 Jul; 78(11):1113-1132. PubMed ID: 30014268
[TBL] [Abstract][Full Text] [Related]
15. Past and present of antiobesity agents: focus on monoamine modulators.
Khorassani FE; Misher A; Garris S
Am J Health Syst Pharm; 2015 May; 72(9):697-706. PubMed ID: 25873617
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
17. Phentermine and topiramate extended-release for the obesity: new kids on the block.
Katsi V; Marketou M; Kallistratos MS; Tousoulis D; Makris T; Manolis AJ; Vardas P; Kallikazaros I
Recent Pat Cardiovasc Drug Discov; 2013 Apr; 8(1):35-41. PubMed ID: 23565717
[TBL] [Abstract][Full Text] [Related]
18. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
Milano W; De Biasio V; Di Munzio W; Foggia G; Capasso A
Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1232-1243. PubMed ID: 32410565
[TBL] [Abstract][Full Text] [Related]
19. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
Gorelik E; Gorelik B; Masarwa R; Perlman A; Hirsh-Raccah B; Matok I
Int J Obes (Lond); 2020 May; 44(5):1021-1027. PubMed ID: 32152496
[TBL] [Abstract][Full Text] [Related]
20. Reducing the risk of obesity: defining the role of weight loss drugs.
Ling H; Lenz TL; Burns TL; Hilleman DE
Pharmacotherapy; 2013 Dec; 33(12):1308-21. PubMed ID: 23712541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
